AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23687218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 84
Study 20096981 — intervention group
Group type: EXPERIMENTAL
Intervention: BioSorb FX biodegradable plates and screws
Number of subjects: 91
Study 20096981 — intervention group
Group type: COMPARATOR
Intervention: Titanium miniplates
Number of subjects: 91
Study 18378836 — intervention group
Group type: EXPERIMENTAL
Intervention: Copay policy (10-25 dollars copayment)
Number of subjects: 0
Study 18378836 — intervention group
Group type: EXPERIMENTAL
Intervention: Income-based deductible policy (25% coinsurance)
Number of subjects: 0
Study 18378836 — intervention group
Group type: COMPARATOR
Intervention: Control (no cost-sharing policy)
Number of subjects: 0
Study 16020489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily
Number of subjects: 2660
Study 16020489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2660
Study 12970006 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC (Fluticasone Propionate 250 microg + Salmeterol 50 microg)
Number of subjects: 723
Study 10434809 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide in oxygen
Number of subjects: 10
Study 10434809 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide in oxygen
Number of subjects: 10
Study 10434809 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide in oxygen
Number of subjects: 10
Study 7833752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness programme (8 exercise classes over 4 weeks)
Number of subjects: 81
Study 7833752 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific exercises and back-school education)
Number of subjects: 81
Study 2163701 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried amniotic membrane applied at the upper half of the wound (36 patients)
Number of subjects: 65
Study 2163701 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried amniotic membrane applied at the lower half of the wound (29 patients)
Number of subjects: 65
Study 2163701 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic-impregnated fine-mesh greased gauze covering remaining areas of the wounds
Number of subjects: 65
Study 326347 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 54239
Study 326347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vole bacillus vaccine
Number of subjects: 54239
Study 326347 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 54239
Study 31124918 — intervention group
Group type: EXPERIMENTAL
Intervention: LI‐GCA patients
Number of subjects: 27
Study 31124918 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 27
Study 31277561 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (150 mg subcutaneously)
Number of subjects: 38
Study 31277561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 27890164 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar task interruption
Number of subjects: 18
Study 27890164 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex task interruption
Number of subjects: 18
Study 27890164 — intervention group
Group type: COMPARATOR
Intervention: No interruption
Number of subjects: 18
Study 25395036 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat, individually adjusted up to a maximum dose of 2.5 mg three times daily
Number of subjects: 237
Study 23519546 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5-40 mg/day
Number of subjects: 491
Study 23519546 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 491
Study 23519546 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol (subgroup analysis for losartan background)
Number of subjects: 491
Study 23519546 — intervention group
Group type: COMPARATOR
Intervention: placebo (subgroup analysis for losartan background)
Number of subjects: 491
Study 23519546 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol (subgroup analysis for lisinopril background)
Number of subjects: 491
Study 23519546 — intervention group
Group type: COMPARATOR
Intervention: placebo (subgroup analysis for lisinopril background)
Number of subjects: 491
Study 23519546 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol
Number of subjects: 491
Study 21660636 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological replacement doses of metreleptin (0.04-0.12 mg/kg q.d.)
Number of subjects: 35
Study 21660636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological doses of metreleptin (0.3 mg/kg)
Number of subjects: 35
Study 21660636 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological doses of metreleptin (0.1 mg/kg)
Number of subjects: 35
Study 21660636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19172849 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin or immunosuppressive therapy
Number of subjects: 63
Study 16878035 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 40,000 units administered weekly for up to 12 doses
Number of subjects: 86
Study 16878035 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 86
Study 16878035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 12634643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 93
Study 12634643 — intervention group
Group type: COMPARATOR
Intervention: Electroablation
Number of subjects: 93
Study 10969657 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 1 evidence (from randomized controlled trials)
Number of subjects: 50
Study 10969657 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 2 evidence (convincing non-experimental evidence)
Number of subjects: 50
Study 10969657 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions without substantial evidence
Number of subjects: 50
Study 9352691 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling Foley catheter
Number of subjects: 100
Study 9352691 — intervention group
Group type: COMPARATOR
Intervention: In-out catheterization
Number of subjects: 100
Study 9352691 — intervention group
Group type: COMPARATOR
Intervention: Catheterized group
Number of subjects: 100
Study 9352691 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncatheterized group
Number of subjects: 100
Study 8222486 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 10 mg
Number of subjects: 30
Study 8222486 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 40 mg
Number of subjects: 30
Study 8222486 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 100 mg
Number of subjects: 30
Study 8222486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8222486 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 (all doses)
Number of subjects: 30
Study 8222486 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219
Number of subjects: 30
Study 3096431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg four times a day
Number of subjects: 4491
Study 3096431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4491
Study 29764392 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 of your 5-a-day smoothie label
Number of subjects: 194
Study 29764392 — intervention group
Group type: COMPARATOR
Intervention: 1 of your 5-a-day smoothie label
Number of subjects: 194
Study 27122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (30 minutes of moderate-intensity) in higher cardiorespiratory fitness group (EIH)
Number of subjects: 60
Study 27122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (30 minutes of moderate-intensity) in lower cardiorespiratory fitness group (EIL)
Number of subjects: 60
Study 27122080 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise intervention)
Number of subjects: 60
Study 24269603 — intervention group
Group type: EXPERIMENTAL
Intervention: All-inside technique
Number of subjects: 46
Study 24269603 — intervention group
Group type: COMPARATOR
Intervention: Classical technique
Number of subjects: 46
Study 21787454 — intervention group
Group type: COMPARATOR
Intervention: Fibre supplement (FIB)
Number of subjects: 3
Study 21787454 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating group with placebo (HLT)
Number of subjects: 3
Study 21787454 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (with placebo)
Number of subjects: 3
Study 20624484 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted NNTs using the ARD approach in RCTs
Number of subjects: 0
Study 20624484 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression with balanced covariates
Number of subjects: 0
Study 20624484 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study 19031218 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifolium pratense-derived isoflavones (80 mg red clover isoflavones) daily for 90 days
Number of subjects: 60
Study 19031218 — intervention group
Group type: COMPARATOR
Intervention: Placebo of equal design
Number of subjects: 60
Study 15538592 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg Hypericum LI 160
Number of subjects: 163
Study 15538592 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 163
Study 15538592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 12647424 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 75‐175 mg daily
Number of subjects: 34
Study 12647424 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 75‐150 mg
Number of subjects: 34
Study 12647424 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg
Number of subjects: 34
Study 10027319 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate/ibuprofen
Number of subjects: 73
Study 10027319 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate/placebo
Number of subjects: 73
Study 8749597 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane-35
Number of subjects: 91
Study 8749597 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon
Number of subjects: 91
Study 2109678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitors
Number of subjects: 0
Study 7016450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate (200 to 400 mg daily)
Number of subjects: 0
Study 7016450 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (2.4 to 4.8 g daily)
Number of subjects: 0
Study 30665602 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous tobacco intervention (TI) combining web-based counseling with nicotine replacement therapy (NRT) during weeks 1-12.
Number of subjects: 67
Study 30665602 — intervention group
Group type: COMPARATOR
Intervention: Sequential tobacco intervention (TI) delayed until weeks 13-24.
Number of subjects: 67
Study 30131639 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removal of caries (Group I)
Number of subjects: 49
Study 30131639 — intervention group
Group type: COMPARATOR
Intervention: Total removal of caries (Group II)
Number of subjects: 49
Study 27108936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanoxerine 400 mg
Number of subjects: 41
Study 27108936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24937907 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: heavy metal music (13 participants)
Number of subjects: 39
Study 24937907 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: classical music (13 participants)
Number of subjects: 39
Study 24937907 — intervention group
Group type: COMPARATOR
Intervention: Group 3: no music (13 participants)
Number of subjects: 39
Study 22160549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine pretreatment (1% lidocaine 2 ml)
Number of subjects: 121
Study 22160549 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment (normal saline 2 ml)
Number of subjects: 121
Study 20962315 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-controlled diet
Number of subjects: 20
Study 20962315 — intervention group
Group type: COMPARATOR
Intervention: Fat-controlled diet
Number of subjects: 20
Study 16884794 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood reduced glutathione (GSH)
Number of subjects: 52
Study 16884794 — intervention group
Group type: EXPERIMENTAL
Intervention: Malondialdehyde (MDA)
Number of subjects: 52
Study 16884794 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 52
Study 16884794 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased blood GSH concentrations
Number of subjects: 52
Study 16884794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic CHF etiology
Number of subjects: 52
Study 16884794 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ischemic CHF etiology
Number of subjects: 52
Study 16258083 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with paclitaxel after doxorubicin and cyclophosphamide (AC)
Number of subjects: 1664
Study 16258083 — intervention group
Group type: COMPARATOR
Intervention: Control group (AC followed by paclitaxel without trastuzumab)
Number of subjects: 1664
Study 11853711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% isopropyl unoprostone (Rescula) applied twice a day for 21 days
Number of subjects: 11
Study 11853711 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice a day for 21 days
Number of subjects: 11
Study 11853711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% isopropyl unoprostone (Rescula)
Number of subjects: 11
Study 9798136 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625‐mg conjugated equine estrogen plus 5‐mg medroxyprogesterone acetate (MPA)
Number of subjects: 37
Study 9798136 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625‐mg conjugated equine estrogen plus 2.5‐mg MPA
Number of subjects: 37
Study 7825160 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of warfarin per day for 3 days (Group I)
Number of subjects: 0
Study 7825160 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of warfarin twice a day for 2 or 3 days (Group II)
Number of subjects: 0
Study 7825160 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group I and Group II)
Number of subjects: 0
Study 7825160 — intervention group
Group type: COMPARATOR
Intervention: Factor X levels in both groups (Group I and Group II)
Number of subjects: 0
Study 3364147 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg.kg‐1 of 1.5% lidocaine
Number of subjects: 0
Study 3364147 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 mg.kg‐1 of 0.5% bupivacaine
Number of subjects: 0
Study 30305343 — intervention group
Group type: EXPERIMENTAL
Intervention: INPUT program
Number of subjects: 268
Study 30305343 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 268
Study 28033291 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 60
Study 28033291 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 60
Study 24302687 — intervention group
Group type: EXPERIMENTAL
Intervention: Early iron (EI) supplementation (2 mg/kg/day elemental iron)
Number of subjects: 104
Study 24302687 — intervention group
Group type: COMPARATOR
Intervention: Late iron (LI) supplementation
Number of subjects: 104
Study 22273632 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1 receptor antagonist (IL‐1Ra) 150 mg
Number of subjects: 11
Study 22273632 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo 1 ml
Number of subjects: 11
Study 20381662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 20
Study 20381662 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 20
Study 18308154 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit-resistance exercise at 40% of 1RM
Number of subjects: 20
Study 18308154 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit-resistance exercise at 60% of 1RM
Number of subjects: 20
Study 18308154 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit-resistance exercise at 80% of 1RM
Number of subjects: 20
Study 18308154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined loads (40+80+80%)
Number of subjects: 20
Study 16132790 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 258
Study 16132790 — intervention group
Group type: COMPARATOR
Intervention: Mail intervention
Number of subjects: 258
Study 14739212 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin 100 mg daily
Number of subjects: 160
Study 14739212 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin enoxaparin 40 mg
Number of subjects: 160
Study 10690604 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy (1% polidocanol)
Number of subjects: 52
Study 10690604 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion (50 micrograms/h for 12 hours following initial 50 micrograms i.v. bolus)
Number of subjects: 52
Study 9369912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment of cisplatin‐based chemotherapy and radiotherapy
Number of subjects: 0
Study 9369912 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radiotherapy
Number of subjects: 0
Study 9369912 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin‐based chemotherapy regimen
Number of subjects: 0
Study 8335204 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme arginate (3 mg/kg)
Number of subjects: 8
Study 8335204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of heme arginate (3 mg/kg) and tin protoporphyrin (1 mumol/kg)
Number of subjects: 8
Study 8335204 — intervention group
Group type: COMPARATOR
Intervention: Tin protoporphyrin (1 mumol/kg)
Number of subjects: 8
Study 8335204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8335204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Heme arginate + Tin protoporphyrin)
Number of subjects: 8
Study 3090961 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase-heparin (Group I)
Number of subjects: 67
Study 3090961 — intervention group
Group type: COMPARATOR
Intervention: Lysyl-plasminogen-urokinase-heparin (Group II)
Number of subjects: 67
Study 2544688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent metoclopramide (regimen A): lorazepam 1 mg orally, dexamethasone 10 mg IV every four hours for three doses, diphenhydramine 0.5 mg/kg IV every four hours for three doses, metoclopramide 1 mg/kg IV bolus every two hours for six doses
Number of subjects: 60
Study 2544688 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion metoclopramide (regimen B): identical to regimen A except metoclopramide was administered as 1 mg/kg IV bolus followed by 0.5 mg/kg/h for ten hours
Number of subjects: 60
Study 31147675 — intervention group
Group type: EXPERIMENTAL
Intervention: ipatasertib plus paclitaxel
Number of subjects: 151
Study 31147675 — intervention group
Group type: COMPARATOR
Intervention: placebo plus paclitaxel
Number of subjects: 151
Study 28651898 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning (RIPC)
Number of subjects: 40
Study 28651898 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 40
Study 23849614 — intervention group
Group type: EXPERIMENTAL
Intervention: Breeze cement (Sub-group A, L, C)
Number of subjects: 45
Study 23849614 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscem cement (Sub-group A, L, C)
Number of subjects: 45
Study 23849614 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite (Sub-group A, L, C)
Number of subjects: 45
Study 21493910 — intervention group
Group type: EXPERIMENTAL
Intervention: SSMP (Stroke Self-Management Program, 8 weeks)
Number of subjects: 143
Study 21493910 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic self-management program (6 weeks)
Number of subjects: 143
Study 21493910 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 143
Study 21493910 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic self-management program
Number of subjects: 143
Study 21493910 — intervention group
Group type: EXPERIMENTAL
Intervention: SSMP
Number of subjects: 143
Study 19833860 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/d for 7 days
Number of subjects: 62
Study 19833860 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 1800 mg/d for 7 days
Number of subjects: 62
Study 19833860 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive calibrator)
Number of subjects: 62
Study 19833860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16721396 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural mixed carotenoids supplementation (120,000 IU of beta-carotene daily)
Number of subjects: 331
Study 16721396 — intervention group
Group type: COMPARATOR
Intervention: Conventional management with multivitamins (including vitamin A and trace elements)
Number of subjects: 331
Study 16721396 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural mixed carotenoids supplementation
Number of subjects: 331
Study 16721396 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline serum carotene concentrations
Number of subjects: 331
Study 16721396 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline CD4 T‐lymphocyte counts
Number of subjects: 331
Study 15121646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/day
Number of subjects: 16
Study 15121646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg/day
Number of subjects: 16
Study 15121646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 120 mg/day
Number of subjects: 16
Study 15121646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 16
Study 15121646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (all doses)
Number of subjects: 16
Study 11719126 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged instruction (bronze stage: 50 compressions with pauses, silver stage: 50 compressions to 5 breaths, gold stage: conventional CPR)
Number of subjects: 495
Study 11719126 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR training
Number of subjects: 495